XML 61 R47.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Revenue Recognition (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Revenue Recognition |
Schedule of disaggregation of revenue |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended December 31,
​ |  | 2024 |  | 2023 |  | 2022
Collaborative revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (KORSUVA injection profit sharing) | ​ | $ | 2,086 | ​ | $ | 12,397 | ​ | $ | 16,572
Maruishi | ​ | ​ | — | ​ | ​ | 539 | ​ | ​ | —
Total collaborative revenue | ​ | $ | 2,086 | ​ | $ | 12,936 | ​ | $ | 16,572
Commercial supply revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor* (KORSUVA injection) | ​ | $ | 640 | ​ | $ | 5,843 | ​ | $ | 10,223
Total commercial supply revenue | ​ | $ | 640 | ​ | $ | 5,843 | ​ | $ | 10,223
License and milestone fees | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor* | ​ | $ | — | ​ | $ | — | ​ | $ | 15,000
Maruishi | ​ | ​ | — | ​ | ​ | 910 | ​ | ​ | —
Total license and milestone fees | ​ | $ | — | ​ | $ | 910 | ​ | $ | 15,000
Royalty revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (Kapruvia ex U.S.) | ​ | $ | — | ​ | $ | 415 | ​ | $ | 72
Total royalty revenue | ​ | $ | — | ​ | $ | 415 | ​ | $ | 72
Clinical compound revenue | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Maruishi | ​ | $ | 84 | ​ | $ | 165 | ​ | $ | —
Total clinical compound revenue | ​ | $ | 84 | ​ | $ | 165 | ​ | $ | —
Other revenue (non-cash) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
CSL Vifor (Kapruvia ex U.S.) | ​ | $ | 1,492 | ​ | $ | 284 | ​ | $ | —
Maruishi | ​ | ​ | 2,835 | ​ | ​ | 415 | ​ | ​ | —
Total other revenue | ​ | $ | 4,327 | ​ | $ | 699 | ​ | $ | —
* Includes amounts earned from Vifor Fresenius Medical Care Renal Pharma Ltd. and Vifor International prior to Vifor International’s assignment of its rights and obligations to Vifor Fresenius Medical Care Renal Pharma Ltd. in May 2022.

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration